Remove QALYs From Orphan HTA Assessments, Says Irish Bill
An Irish private members bill aims to exempt orphan drugs from health technology appraisals based on incremental cost-effectiveness ratio thresholds and quality adjusted life years.
You may also be interested in...
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.
Innovators warn against slashing incentives and argue a lack of a common definition of unmet need is a stumbling block to proposals.